JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...

PARIS — Long-term results from the ALLEGRO clinical trial program of Pfizer’s JAK inhibitor ritlecitinib for severe alopecia areata showed that complete scalp regrowth occurred in a good proportion of ...

Two different drugs that target the Janus kinase (JAK) pathway have shown promise for alopecia areata (AA), inducing hair growth in a large proportion of participants in two separate small studies.

Arash Mostaghimi, MD, MPA, MPH, director of the inpatient dermatology consult service at Brigham & Women's Hospital, discusses the utility of deuruxolitinib for treating moderate to severe alopecia ...